NCT01380392

Unknown

The Illness of Uncertainty, Personality and Coping Strategie...

National Taiwan University Hospital Source

Compare

Other study identifiers

Sponsor study identifier

201101063RC

Study Type

observational

Estimated enrollment

200

Locations

1 country

Sites

1

Timeline

Study Start

February 2011

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

February 2012

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

February 2012

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Brief Summary

The aims of this study are to (1) understand the uncertainty , personality and coping strategies in patients with HCC, and identify the significant factors for coping.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: unknown
Estimated enrollment: 200 participants
Study completion date: February 2012
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
February 2011
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
June 22, 2011
Actual (reported)
First Posted
June 27, 2011
Actual (reported)
Primary Completion
February 2012
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
February 2012
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated: June 27, 2011
Status Verified: June 2011
Last Update Submitted: June 23, 2011

Conditions

Liver Carcinoma

Keywords

Liver cancerUncertaintyPersonalitycoping strategies

Eligibility Criteria

Age20 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

HCC patients who accept surgical or medical treatment.

You may qualify if:

Adult
Has HCC and knows condition
Con's clear
Agree join the study

You may not qualify if:

Sponsors & Collaborators

National Taiwan University Hospital
Otherlead

Study Sites (1)

Research Nurse

Taipei, 110, Taiwan

RECRUITING

Wu Ruei-Jhu, MasterCONTACT+886933037480 r98426022@ntu.edu.tw

MeSH Terms

Conditions

Carcinoma, HepatocellularLiver Neoplasms

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Study Officials

Shiow-Ching Shun, Doctor
National Taiwan University
STUDY CHAIR

Central Study Contacts

Wu Ruei-Jhu, Master

CONTACT

+886933037480 r98426022@ntu.edu.tw

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: CROSS SECTIONAL
Sponsor Type: OTHER

Study Record Dates

First Submitted

June 22, 2011

First Posted

June 27, 2011

Study Start

February 2011

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

February 2012

Estimated (date passed)

NCT02305459

CIRSE Registry for SIR-Spheres Therapy

Completed

NCT01717729

Hepatocellular Carcinoma Treated With Iodine-125 Implantation

Phase 3Completed

NCT00328770

De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma

Phase 2/3Completed

NCT05681234

Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma

Not ApplicableCompleted

NCT06966986

Radiofrequency-responsive Layered Double Hydroxides for Enhanced Arterial Embolization and Thermal Immunotherapy in Hepatocellular Carcinoma

Active Not Recruiting

NCT04443322

Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )

Not ApplicableUnknown

BCLC stage C or D

Accepted C/T, R/T,target therapy or supportive care

Patient who receive liver transplantation

Contact the study team to confirm eligibility.

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

February 2012

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated

June 27, 2011

Record last verified: 2011-06

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT01380392
Data provider: ClinicalTrials.gov
Source updated: 2011-06-27
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:21:47 UTC

Locations

TW(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations